EICHORCondition: Non-Small Cell Lung Cancer · Sponsor: Hoffmann-La Roche
This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) NSCLC staging system.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Northwest Cancer Specialists, P.C. | Tigard, Oregon, United States | — |
| Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | — |
| Peter MacCallum Cancer Centre | Melbourne, Victoria, Australia | — |
| One Clinical Research | Nedlands, Western Australia, Australia | — |
| UZ Gent | Ghent, Belgium | — |
| Hospital de Cancer de Barretos | Barretos, São Paulo, Brazil | — |
| Instituto do Cancer do Estado de Sao Paulo - ICESP | São Paulo, São Paulo, Brazil | — |
| RedSalud Vitacura | Santiago, Chile | — |
| Hunan Cancer Hospital | Changsha, China | — |
| Xinqiao Hospital of Third Military Medical University | Chongqing, China | — |
| Shandong Cancer Hospital | Jinan, China | — |
| Shanghai Pulmonary Hospital | Shanghai, China | — |
+ 33 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05170204